Relationship between MAN2B1 genotype/subcellular localization subgroups, antidrug antibody detection, and long‐term velmanase alfa treatment outcomes in patients with alpha‐mannosidosis
Abstract Alpha‐mannosidosis (AM), an autosomal recessive disorder caused by pathogenic biallelic variants in the MAN2B1 gene, leads to lysosomal alpha‐mannosidase deficiency and accumulation of mannose‐rich oligosaccharides. Velmanase alfa (VA), a recombinant human lysosomal alpha‐mannosidase, is th...
Main Authors: | Line Gutte Borgwardt, Ferdinando Ceravolo, Giulia Zardi, Andrea Ballabeni, Allan Meldgaard Lund |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-03-01
|
Series: | JIMD Reports |
Subjects: | |
Online Access: | https://doi.org/10.1002/jmd2.12349 |
Similar Items
-
Velmanase alfa approved for treatment of non-central nervous system manifestations of alpha-mannosidosis: A therapeutics bulletin of the American College of Medical Genetics and Genomics (ACMG)
by: Julie M. Lander, et al.
Published: (2024-01-01) -
Cost-effectiveness of velmanase alfa vs. bone marrow transplantation or no causal therapy in patients with mild to moderate alpha-mannosidosis
by: Ana Antanasković, et al.
Published: (2023-12-01) -
The Application of HPLC-FLD and NMR in the Monitoring of Therapy Efficacy in Alpha-Mannosidosis
by: Maroš Krchňák, et al.
Published: (2023-02-01) -
Carrier frequency and incidence of alpha-mannosidosis: population database-based study—focus on the East Asian and Korean population
by: Jong Eun Park, et al.
Published: (2023-12-01) -
Case report of a novel homozygous variant in a Saudi patient with alpha mannosidosis
by: Rehab Al Jawad, et al.
Published: (2021-12-01)